HC Wainwright Trims RegeneRx Biopharmaceuticals Inc. (RGRX) Target Price to $1.50
RegeneRx Biopharmaceuticals Inc. (OTC:RGRX) had its target price reduced by HC Wainwright from $2.00 to $1.50 in a research report released on Wednesday morning, StockTargetPrices.com reports. HC Wainwright currently has a buy rating on the stock.
Separately, ValuEngine cut shares of RegeneRx Biopharmaceuticals from a hold rating to a sell rating in a research report on Friday, September 1st.
Shares of RegeneRx Biopharmaceuticals (OTC:RGRX) opened at $0.29 on Wednesday. The stock has a market cap of $31.00, a P/E ratio of 29.00 and a beta of -2.70. The company has a current ratio of 0.39, a quick ratio of 0.39 and a debt-to-equity ratio of -0.10. RegeneRx Biopharmaceuticals has a 1 year low of $0.22 and a 1 year high of $0.40.
RegeneRx Biopharmaceuticals Company Profile
RegeneRx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide.
Receive News & Ratings for RegeneRx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.